The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis

ConclusionsPegaspargase, as part of multi-drug chemotherapy, is a cost-effective option for the treatment of newly diagnosed ALL. Based on this study, The National Institute for Health and Care Excellence Technology Appraisal Committee concluded that it could recommend pegaspargase as a cost-effective use of National Health Service resources in England& Wales for treating ALL in children, young people and adults with untreated, newly diagnosed disease.Trial registrationUKALL 2011, EudraCT number2010-020924-22; UKALL 2003, EudraCT number2007-004013-34; UKALL14, EudraCT number2009-012717-22.
Source: Health Economics Review - Category: International Medicine & Public Health Source Type: research